Cargando…

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators

OBJECTIVE: In HCV infected individuals graft infection occurs shortly after orthotopic liver transplantation (OLT). We aimed to describe the composition of the inflammatory response at this time, how it affects the HCV replication cycle and identify novel proviral and antiviral factors. DESIGN: We u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van, Nguyen Dinh, Falk, Christine S, Sandmann, Lisa, Vondran, Florian W R, Helfritz, Fabian, Wedemeyer, Heiner, Manns, Michael P, Ciesek, Sandra, von Hahn, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893125/ https://www.ncbi.nlm.nih.gov/pubmed/25800783 http://dx.doi.org/10.1136/gutjnl-2014-308003

Ejemplares similares

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
por: Carpentier, Arnaud, et al.
Publicado: (2020)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice
por: Prentoe, Jannick, et al.
Publicado: (2016)

Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells
por: Schlaphoff, Verena, et al.
Publicado: (2011)

Hyperbilirubinaemia in HIV–HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?
por: Kaspar, Matthew B, et al.
Publicado: (2016)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Novel host genetic variations associated with spontaneous clearance of a single-source outbreak of HCV1b infections
por: You, Hong, et al.
Publicado: (2015)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
por: Van Renne, Nicolaas, et al.
Publicado: (2018)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

The paradox of NKp46(+) natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment
por: Pembroke, Tom, et al.
Publicado: (2014)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease
por: Konerman, Monica A, et al.
Publicado: (2019)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells
por: Dai, Zhen, et al.
Publicado: (2020)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study
por: Lin, Ming-Shyan, et al.
Publicado: (2015)

Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
por: Conche, Claire, et al.
Publicado: (2023)

Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids
por: Pfaender, Stephanie, et al.
Publicado: (2018)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study
por: Markby, Jessica, et al.
Publicado: (2021)

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
por: Meyer, Manuela F, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_92voasiqplit8mqf1b3ov1hu7f